Skip to main content
Top
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens

Authors: Audrey Forson, Awewura Kwara, Samuel Kudzawu, Michael Omari, Jacob Otu, Florian Gehre, Bouke de Jong, Martin Antonio

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

Mycobacterium tuberculosis drug resistance is a major challenge to the use of standardized regimens for tuberculosis (TB) therapy, especially among previously treated patients. We aimed to investigate the frequency and pattern of drug resistance among previously treated patients with smear-positive pulmonary tuberculosis at the Korle-Bu Teaching Hospital Chest Clinic, Accra.

Methods

This was a cross-sectional survey of mycobacterial isolates from previously treated patients referred to the Chest Clinic Laboratory between October 2010 and October 2013. The Bactec MGIT 960 system for mycobactrerial culture and drug sensitivity testing (DST) was used for sputum culture of AFB smear-positive patients with relapse, treatment failure, failure of smear conversion, or default. Descriptive statistics were used to summarize patient characteristics, and frequency and patterns of drug resistance.

Results

A total of 112 isolates were studied out of 155 from previously treated patients. Twenty contaminated (12.9%) and 23 non-viable isolates (14.8%) were excluded. Of the 112 studied isolates, 53 (47.3%) were pan-sensitive to all first-line drugs tested Any resistance (mono and poly resistance) to isoniazid was found in 44 isolates (39.3%) and any resistance to streptomycin in 43 (38.4%). Thirty-one (27.7%) were MDR-TB. Eleven (35.5%) out of 31 MDR-TB isolates were pre-XDR. MDR-TB isolates were more likely than non-MDR isolates to have streptomycin and ethambutol resistance.

Conclusions

The main findings of this study were the high prevalence of MDR-TB and streptomycin resistance among previously treated TB patients, as well as a high prevalence of pre-XDR-TB among the MDR-TB patients, which suggest that first-line and second-line DST is essential to aid the design of effective regimens for these groups of patients in Ghana.
Literature
2.
go back to reference Iseman MD. Extensively drug-resistant Mycobacterium tuberculosis: Charles Darwin would understand. Clin Infect Dis. 2007;45(11):1415–6.CrossRefPubMed Iseman MD. Extensively drug-resistant Mycobacterium tuberculosis: Charles Darwin would understand. Clin Infect Dis. 2007;45(11):1415–6.CrossRefPubMed
3.
go back to reference Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2007;45(11):1409–14.CrossRefPubMed Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2007;45(11):1409–14.CrossRefPubMed
4.
go back to reference WHO: Treatment of tuberculosis: guidelines - 4th ed. WHO/HTM/TB/2009.420. 2010. WHO: Treatment of tuberculosis: guidelines - 4th ed. WHO/HTM/TB/2009.420. 2010.
5.
go back to reference Nakanwagi-Mukwaya A, Reid AJ, Fujiwara PI, Mugabe F, Kosgei RJ, Tayler-Smith K, Kizito W, Joloba M. Characteristics and treatment outcomes of tuberculosis retreatment cases in three regional hospitals, Uganda. Public Health Action. 2013;3(2):149–55.CrossRefPubMedPubMedCentral Nakanwagi-Mukwaya A, Reid AJ, Fujiwara PI, Mugabe F, Kosgei RJ, Tayler-Smith K, Kizito W, Joloba M. Characteristics and treatment outcomes of tuberculosis retreatment cases in three regional hospitals, Uganda. Public Health Action. 2013;3(2):149–55.CrossRefPubMedPubMedCentral
6.
go back to reference Ottmani SE, Zignol M, Bencheikh N, Laasri L, Chaouki N, Mahjour J. Results of cohort analysis by category of tuberculosis retreatment cases in Morocco from 1996 to 2003. Int J Tuberc Lung Dis. 2006;10(12):1367–72.PubMed Ottmani SE, Zignol M, Bencheikh N, Laasri L, Chaouki N, Mahjour J. Results of cohort analysis by category of tuberculosis retreatment cases in Morocco from 1996 to 2003. Int J Tuberc Lung Dis. 2006;10(12):1367–72.PubMed
7.
go back to reference Tabarsi P, Chitsaz E, Tabatabaei V, Baghaei P, Shamaei M, Farnia P, Marjani M, Kazempour M, Mansouri D, Masjedi MR, et al. Revised category II regimen as an alternative strategy for retreatment of category I regimen failure and irregular treatment cases. Am J Ther. 2011;18(5):343–9.CrossRefPubMed Tabarsi P, Chitsaz E, Tabatabaei V, Baghaei P, Shamaei M, Farnia P, Marjani M, Kazempour M, Mansouri D, Masjedi MR, et al. Revised category II regimen as an alternative strategy for retreatment of category I regimen failure and irregular treatment cases. Am J Ther. 2011;18(5):343–9.CrossRefPubMed
8.
go back to reference Acuna-Villaorduna C, Ayakaka I, Dryden-Peterson S, Nakubulwa S, Worodria W, Reilly N, Hosford J, Fennelly KP, Okwera A, Jones-Lopez EC. High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. Am J Trop Med Hyg. 2015;93(1):73–5.CrossRefPubMedPubMedCentral Acuna-Villaorduna C, Ayakaka I, Dryden-Peterson S, Nakubulwa S, Worodria W, Reilly N, Hosford J, Fennelly KP, Okwera A, Jones-Lopez EC. High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. Am J Trop Med Hyg. 2015;93(1):73–5.CrossRefPubMedPubMedCentral
9.
go back to reference Kato T, Addo KK, Nartey N, Nyarko AK, Bonsu FA, Mitarai S. First susceptibility testing of Mycobacterium tuberculosis for second-line anti-tuberculosis drugs in Ghana. Trop Med Health. 2014;42(1):53–5.CrossRefPubMedPubMedCentral Kato T, Addo KK, Nartey N, Nyarko AK, Bonsu FA, Mitarai S. First susceptibility testing of Mycobacterium tuberculosis for second-line anti-tuberculosis drugs in Ghana. Trop Med Health. 2014;42(1):53–5.CrossRefPubMedPubMedCentral
10.
go back to reference Ardito F, Posteraro B, Sanguinetti M, Zanetti S, Fadda G. Evaluation of BACTEC mycobacteria growth Indicator tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2001;39(12):4440–4.CrossRefPubMedPubMedCentral Ardito F, Posteraro B, Sanguinetti M, Zanetti S, Fadda G. Evaluation of BACTEC mycobacteria growth Indicator tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2001;39(12):4440–4.CrossRefPubMedPubMedCentral
11.
go back to reference World Health Organization: The Stop TB Department. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. 2008. World Health Organization: The Stop TB Department. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. 2008.
12.
go back to reference Forson A, Kudzawu S, Kwara A, Flanigan T. High frequency of first-line anti-tuberculosis drug resistance among persons with chronic pulmonary tuberculosis at a teaching hospital chest clinic. Ghana Med J. 2010;44(2):42–6.PubMedPubMedCentral Forson A, Kudzawu S, Kwara A, Flanigan T. High frequency of first-line anti-tuberculosis drug resistance among persons with chronic pulmonary tuberculosis at a teaching hospital chest clinic. Ghana Med J. 2010;44(2):42–6.PubMedPubMedCentral
13.
go back to reference Noeske J, Voelz N, Fon E, Abena Foe JL. Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon. BMC Res Notes. 2012;5:160.CrossRefPubMedPubMedCentral Noeske J, Voelz N, Fon E, Abena Foe JL. Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon. BMC Res Notes. 2012;5:160.CrossRefPubMedPubMedCentral
14.
go back to reference Lawson L, Yassin MA, Abdurrahman ST, Parry CM, Dacombe R, Sogaolu OM, Ebisike JN, Uzoewulu GN, Lawson LO, Emenyonu N, et al. Resistance to first-line tuberculosis drugs in three cities of Nigeria. Tropical Med Int Health. 2011;16(8):974–80.CrossRef Lawson L, Yassin MA, Abdurrahman ST, Parry CM, Dacombe R, Sogaolu OM, Ebisike JN, Uzoewulu GN, Lawson LO, Emenyonu N, et al. Resistance to first-line tuberculosis drugs in three cities of Nigeria. Tropical Med Int Health. 2011;16(8):974–80.CrossRef
15.
go back to reference Sangare L, Diande S, Badoum G, Dingtoumda B, Traore AS. Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso. Int J Tuberc Lung Dis. 2010;14(11):1424–9.PubMed Sangare L, Diande S, Badoum G, Dingtoumda B, Traore AS. Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso. Int J Tuberc Lung Dis. 2010;14(11):1424–9.PubMed
16.
go back to reference Owusu-Dabo E, Adjei O, Meyer CG, Horstmann RD, Enimil A, Kruppa TF, Bonsu F, Browne EN, Chinbuah MA, Osei I, et al. Mycobacterium tuberculosis drug resistance, Ghana. Emerg Infect Dis. 2006;12(7):1171–2.CrossRefPubMed Owusu-Dabo E, Adjei O, Meyer CG, Horstmann RD, Enimil A, Kruppa TF, Bonsu F, Browne EN, Chinbuah MA, Osei I, et al. Mycobacterium tuberculosis drug resistance, Ghana. Emerg Infect Dis. 2006;12(7):1171–2.CrossRefPubMed
17.
go back to reference Ponce M, Ugarte-Gil C, Zamudio C, Krapp F, Gotuzzo E, Seas C. Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru. Trans R Soc Trop Med Hyg. 2012;106(8):508–10.CrossRefPubMed Ponce M, Ugarte-Gil C, Zamudio C, Krapp F, Gotuzzo E, Seas C. Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru. Trans R Soc Trop Med Hyg. 2012;106(8):508–10.CrossRefPubMed
18.
go back to reference Lam E, Nateniyom S, Whitehead S, Anuwatnonthakate A, Monkongdee P, Kanphukiew A, Inyaphong J, Sitti W, Chiengsorn N, Moolphate S, et al. Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004-2008. Emerg Infect Dis. 2014;20(3):400–8.CrossRefPubMedPubMedCentral Lam E, Nateniyom S, Whitehead S, Anuwatnonthakate A, Monkongdee P, Kanphukiew A, Inyaphong J, Sitti W, Chiengsorn N, Moolphate S, et al. Use of drug-susceptibility testing for management of drug-resistant tuberculosis, Thailand, 2004-2008. Emerg Infect Dis. 2014;20(3):400–8.CrossRefPubMedPubMedCentral
19.
go back to reference Newman MJ, Frimpong E, Donkor ES, Opintan JA, Asamoah-Adu A. Resistance to antimicrobial drugs in Ghana. Infect Drug Resist. 2011;4:215–20.PubMedPubMedCentral Newman MJ, Frimpong E, Donkor ES, Opintan JA, Asamoah-Adu A. Resistance to antimicrobial drugs in Ghana. Infect Drug Resist. 2011;4:215–20.PubMedPubMedCentral
Metadata
Title
A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens
Authors
Audrey Forson
Awewura Kwara
Samuel Kudzawu
Michael Omari
Jacob Otu
Florian Gehre
Bouke de Jong
Martin Antonio
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3053-5

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.